AIM Company Profile

Below is the information we hold on the AIM company you have chosen to view. As a registered user, you can can view the Share Price, any public documents or presentations on the AIM company plus any additional details. Click on the share price 'Block' and you can view extended charting and share information. 'Bookmark' the company to your own portfolio, print off the page details and download as a 'pdf'. You can also rate this AIM company by simply clicking the 'star' rating. If we hold news on this company, relevant articles will be displayed for you to view. Note: All share information is subject to a 15min. delay.

  1. Pharmaceuticals & Biotechnology
  2. »

Share Activity
Share Activity:

Key Company Info.
Trading Notes:

The company moved from the Main market to AIM on the 4th Feb 2019.

Company Description:

Circassia is a specialty pharmaceutical company focused on respiratory disease. Our growing commercial organization promotes our innovative asthma management products directly to specialist physicians in a number of key markets, and we market the chronic obstructive pulmonary disease (COPD) product Tudorza® in the United States. We are expanding our commercial platform in China, and are working to expand our portfolio through in-licensing, partnering or acquisition.

Our asthma management products

Our market-leading NIOX® products are used by specialists around the world to aid asthma diagnosis and management. We sell NIOX® direct in the United States, United Kingdom and Germany, and we are strengthening our presence in Europe and China. Our NIOX® products are also supplied in many other countries through our international network of partners.

Our US commercial collaboration

We collaborate with AstraZeneca in the United States, where we promote the COPD product Tudorza®. We also have the US commercial rights to Duaklir®*, for which AstraZeneca submitted a New Drug Application in Q2 2018. Both products feature the novel Pressair® device. As part of our collaboration we significantly expanded our US salesforce and strengthened our commercial team.

Our respiratory pipeline

Our lead asthma product targets substitution of GSK’s Flixotide® pMDI, and we have a product candidate targeting direct substitution of Seretide® pMDI. We also have a number of chronic obstructive pulmonary disease treatment candidates, including novel formulations of currently approved drugs and a substitute for Spiriva Handihaler®. We are seeking development partners for our pipeline products as part of our commercially-focused investment strategy.

Our history

Circassia was established in 2006, and in March 2014 we completed an initial public offering on the London Stock Exchange.  In June 2015, we completed the acquisitions of Aerocrine and Prosonix as part of our strategy to independently commercialize our products and broaden our pipeline, and in April 2017 we established a commercial collaboration with AstraZeneca in the United States.

*The Duaklir® trademark is registered in the United States; the mark is not currently approved for use by the FDA.
Active: Trading


List date: 4th February 2019 08:00


Nominated Advisor:

Peel Hunt LLP


Peel Hunt LLP

Contact Information
You must be logged in to see this info

Send message to moderator

If this profile is about your AIM company, but the information is limited you can add to the information we hold. The company displayed HERE is a typical example of the type of information we can display about your company. Good promotion of your AIM listed company is critical for exposure to potential investors and liquidity in shares. Get in touch HERE if you would like to know more about how we can help promote your AIM listed company.